Microcirculatory alterations in ischemia-reperfusion injury and sepsis: Effects of activated protein C and thrombin inhibition

Critical Care

Volumn 9, Issue SUPPL. 4, 2005, Pages

  Hoffmann, Johannes N ^a   Vollmar, Brigitte ^b   Laschke, Matthias W ^b   Fertmann, Jan M ^a   Jauch, Karl Walter ^a   Menger, Michael D ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10A; CELL ADHESION MOLECULE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; HEPARIN; HIRUDIN; PLACEBO; THROMBIN; THROMBIN INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CELL INTERACTION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTOXEMIA; FLUORESCENCE MICROSCOPY; INFLAMMATION; ISCHEMIA; LEUKOCYTE ADHERENCE; MICROCIRCULATION; MULTIPLE ORGAN FAILURE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS;

ANIMALS; ANTICOAGULANTS; HUMANS; KIDNEY; MICROCIRCULATION; PROTEIN C; REPERFUSION INJURY; SEPSIS; THROMBIN;

EID: 27144476216     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc3758     Document Type: Review

References (31)

1. Bone RC: Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992, 152:1381-1389.
2. Yan SB: Activated protein C versus protein C in severe sepsis. Crit Care Med 2001, 29:S69-S74.
3. Krishnamurti C, Young GD, Barr CF, Colleton CA, Alving BM: Enhancement of tissue plasmin activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits. J Lab Clin Med 1991, 118:523-530.
4. Hoffmann JN, Mühlbayer D, Jochum M, Inthorn D: Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004, 32:1851-1859.
5. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992, 101:816-823.
6. Mesters RM, Helterbrand JD, Utterback BG, Yan SB, Chao YB, Fernandez JA, Griffin JH, Hartmann DL: Prognostic value of protein C concentrations in neutropenic patients at risk of severe septic complications. Crit Care Med 2000, 28:2209-2216.
7. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW: Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN gamma, or phorbol ester. J Immunol 1994, 153:3664-3672.
8. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, Neill L, Kelleher D, Schwarz HP, Smith OP: Activated protein C inhibits lipopolysaccharide induced nuclear translocation of nuclear factor κB (NF-κB) and tumor necrosis factor (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000, 110:130-134.
9. Esmon CT: Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000, 95:1113-1116.
10. Taylor FBJ, Chang A, Esmon CT, D'Angelo A, Vigano DA, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987, 79: 918-925.
11. Roback MG, Stack AM, Thompson C, Brugnara C, Schwarz HP, Saladino RA: Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock 1998, 9: 138-142.
12. Murakami K, Okajima K, Uchiba M: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leucocytes in rats. Blood 1996, 87:642-647.
13. Grinnell BW, Herman RB, Yan SB: Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharid. Glycobiology 1994, 4:221-224.
14. Butcher EC: Leucocyte-endothelial cell recognition - three or more steps to specificity and diversity. Cell 1991, 67:1033-1036.
15. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150.
16. de Backer D, Creteur J, Pricer JC, Dubois MJ, Vincent JL: Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002, 166:98-104.
17. Lam C, Tymi K, Martin C, Sibbald W: Microvascular perfusion is impaired in a rat model of normotensive sepsis. J Clin Invest 1994, 94:2077-2083.
18. Kishimoto TK, Larson RS, Corbi AL, Dustin ML, Staunton DE, Springer TA: The leucocyte integrins. Adv Immunol 1989, 46: 149-182.
19. Rothlein R, Wegner C: Role of intercellular adhesion molecule-1 in the inflammatory response. Kidney Int 1992, 41:617-619.
20. McCuskey R, Urbaschek R, Urbaschek B: The microcirculation during endotoxinemia. Cardiovasc Res 1996, 32:752-763.
21. Stricter RM, Kunkel SL: Acute lung injury: the role of cytokines in the elicitation of neutrophils. J Invest Med 1994, 42:643-649.
22. Park CT, Creasey AA, Wright SD: Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD 14. Blood 1997, 89:4268-4274.
23. Johnston B, Walter UM, Issekutz AC, Issekutz TB, Anderson DC, Kubes P: Differential roles of selectins and the alpha4-integrin in acute, subacute, and chronic leucocyte recruitment in vivo. J Immunol 1997, 159:4514-4523.
24. Hoffmann JN, Faist E: Coagulation inhibitor replacement during sepsis: useless? Crit Care Med 2000, 28:S74-S76.
25. Mizutani A, Okajima K, Uchiba M, Noguchi T: Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leucocyte activation. Blood 2000, 95:3781-3787.
26. Schoots IG, Levi M, van Vliet AK, Maas AM, Rossink EH, van Gulik TM: Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 2004, 32: 1375-1383.
27. Yamaguchi Y, Hisama N, Okajima K, Uchiba M, Murakami K, Takahashi Y, Yamada S, Mori K, Ogawa M: Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia reperfusion. Hepatology 1997, 25:1136-1140.
28. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD: A chronic model for intravital microscopic study of microcirculatory disorders and leucocyte/endothelial cell interaction during normotensive endotoxinemia. Shock 1999, 12:355-364.
29. Hoffmann JN, Vollmar B, Laschke M, Inthorn D, Schildberg FW, Menger MD: Hydroxyethyl starch (130 kD) but not crystalloid volume support improves microcirculation during normotensive endotoxemia. Anesthesiology 2002, 97:460-470.
30. Hoffmann JN, Vollmar B, Laschke M, Inthorn D, Fertmann J, Schildberg FW, Menger MD: Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004, 32:1011-1017.
31. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD: The thrombin antagonist hirudin fails to inhibit endotoxin-induced leucocyte/endothelial cell interaction and microvascular perfusion failure. Shock 2000, 14:528-534.